Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer Disease

19Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The Alzheimer amyloid protein precursor (APP) is subject to proteolysis by ADAM10 and ADAM17, precluding the formation of Aβ. Recently, coding variations in ADAM10 resulting in altered function have been reported in familial Alzheimer disease (AD). The authors carried out a large-scale (n = 576: Controls, 271; AD, 305) resequencing study of ADAM10 in sporadic AD. The results do not support a significant role for ADAM10 mutations in AD. The results also make it clear that the careful examination of ancestry required in any case-control comparison is especially true with rare variations, where even a very small number of variations might form the basis of scientific conclusions. © 2012 Elsevier Inc.

Cite

CITATION STYLE

APA

Cai, G., Atzmon, G., Naj, A. C., Beecham, G. W., Barzilai, N., Haines, J. L., … Buxbaum, J. D. (2012). Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer Disease. Neurobiology of Aging, 33(2). https://doi.org/10.1016/j.neurobiolaging.2010.03.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free